scholarly journals Comparative evaluation of intranasally delivered quetiapine loaded mucoadhesive microemulsion and polymeric nanoparticles for brain targeting: pharmacokinetic and gamma scintigraphy studies

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Brijesh Shah ◽  
Dignesh Khunt ◽  
Manju Misra
Keyword(s):  
Polymeric Nanoparticles ◽  
Synergistic Effects ◽  
Drug Loading ◽  
Imaging Study ◽  
Gamma Scintigraphy ◽  
Nasal Delivery ◽  
Brain Targeting ◽  
Globule Size ◽  
The Brain

Abstract Background Treatment in neurological disorders like schizophrenia requires continuous presence of drug in the brain for a prolonged period of time to achieve an effective therapeutic response. Delivery of antipsychotic drug quetiapine in the form of conventional delivery systems suffers from low oral bioavailability, first-pass metabolism, and frequent dosing. In addition to that biological obstacles present at the brain interface also hinders the transport of quetiapine across the brain. In the present study, nasal delivery of quetiapine loaded nanoparticles and microemulsion formulation were designed to evaluate their individual in vivo potential to achieve brain targeting. Chitosan-based polymeric nanoparticles and mucoadhesive microemulsion systems were developed through ionic gelation and water titration method respectively. Results Microemulsion showed globule size lower than 50 nm with 95% drug loading while, nanoparticles exhibited 65% drug loading with particle size of 131 nm. Nasal diffusion study showed highest diffusion with chitosan-based mucoadhesive microemulsion over nanoparticles suggesting permeation-enhancing effects of chitosan. Due to the overall hydrophilic nature, quetiapine-loaded nanoparticles could not diffuse superiorly across nasal mucosa, hence, showed 1.3 times lesser diffusion compared to mucoadhesive microemulsion. Pharmacokinetics in rats showed highest brain concentration and 1.9-folds higher nasal bioavailability with mucoadhesive microemulsion over nanoparticles suggesting direct brain transport through olfactory route bypassing blood-brain barrier. Conclusion Higher quetiapine transport with mucoadhesive microemulsion suggested that synergistic effects like tight junction modulation by chitosan and unique composition facilitating smaller globule size could be responsible for higher brain transport. Imaging study by gamma scintigraphy also supported pharmacokinetic outcomes and concluded that mucoadhesive microemulsion could be a promising nanocarrier approach for non-invasive nose to brain delivery. Graphical abstract

Polymeric Nanoparticles for Brain Drug Delivery - A Review

2020 ◽  
Vol 21 (9) ◽  
pp. 649-660
Author(s):  
Subashini Raman ◽  
Syed Mahmood ◽  
Ayah R. Hilles ◽  
Md Noushad Javed ◽  
Motia Azmana ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Surface Modification ◽  
Polymeric Nanoparticles ◽  
Drug Loading ◽  
Preparation Methods ◽  
Brain Drug Delivery ◽  
Polymeric Nanoparticle ◽  
Relationship Of ◽  
The Relationship ◽  
The Brain

Background: Blood-brain barrier (BBB) plays a most hindering role in drug delivery to the brain. Recent research comes out with the nanoparticles approach, is continuously working towards improving the delivery to the brain. Currently, polymeric nanoparticle is extensively involved in many therapies for spatial and temporal targeted areas delivery. Methods: We did a non-systematic review, and the literature was searched in Google, Science Direct and PubMed. An overview is provided for the formulation of polymeric nanoparticles using different methods, effect of surface modification on the nanoparticle properties with types of polymeric nanoparticles and preparation methods. An account of different nanomedicine employed with therapeutic agent to cross the BBB alone with biodistribution of the drugs. Results: We found that various types of polymeric nanoparticle systems are available and they prosper in delivering the therapeutic amount of the drug to the targeted area. The effect of physicochemical properties on nanoformulation includes change in their size, shape, elasticity, surface charge and hydrophobicity. Surface modification of polymers or nanocarriers is also vital in the formulation of nanoparticles to enhance targeting efficiency to the brain. Conclusion: More standardized methods for the preparation of nanoparticles and to assess the relationship of surface modification on drug delivery. While the preparation and its output like drug loading, particle size, and charge, permeation is always conflicted, so it requires more attention for the acceptance of nanoparticles for brain delivery.

scholarly journals Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS

Pharmaceutics ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 1059
Author(s):  
Saif Ahmad Khan ◽  
Saleha Rehman ◽  
Bushra Nabi ◽  
Ashif Iqubal ◽  
Nida Nehal ◽  
...  
Keyword(s):  
Targeted Delivery ◽  
Drug Loading ◽  
Entrapment Efficiency ◽  
Fold Increase ◽  
Pharmacokinetic Studies ◽  
Nanostructured Lipid Carrier ◽  
Brain Delivery ◽  
The Brain

Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of excipients can be a potential approach for overcoming the limited ATZ brain delivery. Methods: ATZ-loaded NLC was formulated using the quality by design-enabled approach and further optimized by employing the Box–Behnken design. The optimized nanoformulation was then characterized for several in vitro and in vivo assessments. Results: The optimized NLC showed small particle size of 227.6 ± 5.4 nm, high entrapment efficiency (71.09% ± 5.84%) and high drug loading capacity (8.12% ± 2.7%). The release pattern was observed to be biphasic exhibiting fast release (60%) during the initial 2 h, then trailed by the sustained release. ATZ-NLC demonstrated a 2.36-fold increase in the cumulative drug permeated across the rat intestine as compared to suspension. Pharmacokinetic studies revealed 2.75-folds greater Cmax in the brain and 4-fold improvement in brain bioavailability signifying the superiority of NLC formulation over drug suspension. Conclusion: Thus, NLC could be a promising avenue for encapsulating hydrophobic drugs and delivering it to their target site. The results suggested that increase in bioavailability and brain-targeted delivery by NLC, in all plausibility, help in improving the therapeutic prospects of atazanavir.

scholarly journals The Antibiofilm Nanosystems for Improved Infection Inhibition of Microbes in Skin

Molecules ◽  
2021 ◽  
Vol 26 (21) ◽  
pp. 6392
Author(s):  
Yin-Ku Lin ◽  
Shih-Chun Yang ◽  
Ching-Yun Hsu ◽  
Jui-Tai Sung ◽  
Jia-You Fang
Keyword(s):  
Polymeric Nanoparticles ◽  
Close Contact ◽  
Drug Stability ◽  
Drug Loading ◽  
Metal Oxide Nanoparticles ◽  
Skin Infections ◽  
Novel Approach ◽  
The Matrix ◽  
Infection Inhibition

Biofilm formation is an important virulence factor for the opportunistic microorganisms that elicit skin infections. The recalcitrant feature of biofilms and their antibiotic tolerance impose a great challenge on the use of conventional therapies. Most antibacterial agents have difficulty penetrating the matrix produced by a biofilm. One novel approach to address these concerns is to prevent or inhibit the formation of biofilms using nanoparticles. The advantages of using nanosystems for antibiofilm applications include high drug loading efficiency, sustained or prolonged drug release, increased drug stability, improved bioavailability, close contact with bacteria, and enhanced accumulation or targeting to biomasses. Topically applied nanoparticles can act as a strategy for enhancing antibiotic delivery into the skin. Various types of nanoparticles, including metal oxide nanoparticles, polymeric nanoparticles, liposomes, and lipid-based nanoparticles, have been employed for topical delivery to treat biofilm infections on the skin. Moreover, nanoparticles can be designed to combine with external stimuli to produce magnetic, photothermal, or photodynamic effects to ablate the biofilm matrix. This study focuses on advanced antibiofilm approaches based on nanomedicine for treating skin infections. We provide in-depth descriptions on how the nanoparticles could effectively eliminate biofilms and any pathogens inside them. We then describe cases of using nanoparticles for antibiofilm treatment of the skin. Most of the studies included in this review were supported by in vivo animal infection models. This article offers an overview of the benefits of nanosystems for treating biofilms grown on the skin.

Stimuli-responsive Polymeric nanosystems for therapeutic applications

2021 ◽  
Vol 27 ◽  
Author(s):  
Mayank Handa ◽  
Ajit Singh ◽  
S.J.S. Flora ◽  
Rahul Shukla
Keyword(s):  
Drug Delivery ◽  
Metallic Nanoparticles ◽  
Drug Delivery Systems ◽  
Polymeric Nanoparticles ◽  
Drug Loading ◽  
Delivery Systems ◽  
Specific Drug ◽  
Stimuli Responsive

Background: Recent past decades have reported emerging of polymeric nanoparticles as a promising technique for controlled and targeted drug delivery. As nanocarriers, they have high drug loading and delivery to the specific site or targeted cells with an advantage of no drug leakage within en route and unloading of a drug in a sustained fashion at the site. These stimuli-responsive systems are functionalized in dendrimers, metallic nanoparticles, polymeric nanoparticles, liposomal nanoparticles, quantum dots. Purpose of Review: The authors reviewed the potential of smart stimuli-responsive carriers for therapeutic application and their behavior in external or internal stimuli like pH, temperature, redox, light, and magnet. These stimuli-responsive drug delivery systems behave differently in In vitro and In vivo drug release patterns. Stimuli-responsive nanosystems include both hydrophilic and hydrophobic systems. This review highlights the recent development of the physical properties and their application in specific drug delivery. Conclusion: The stimuli (smart, intelligent, programmed) drug delivery systems provide site-specific drug delivery with potential therapy for cancer, neurodegenerative, lifestyle disorders. As development and innovation, the stimuli-responsive based nanocarriers are moving at a fast pace and huge demand for biocompatible and biodegradable responsive polymers for effective and safe delivery.

scholarly journals Brain Targeting of anti-HIV Nucleosides: in vitro and in vivo Evaluation of 6-chloro-2′,3′-dideoxypurine, a Lipophilic Prodrug of 2′,3′-dideoxyinosine

1994 ◽  
Vol 5 (5) ◽  
pp. 304-311 ◽  
Author(s):  
K. J. Doshi ◽  
F. D. Boudinot ◽  
J. M. Gallo ◽  
R. F. Schinazi ◽  
C. K. Chu
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Oral Administration ◽  
Intravenous Administration ◽  
Brain Targeting ◽  
The Central Nervous System ◽  
Intravenous And Oral Administration ◽  
The Brain

Lipophilic 6-halo-2′,3′-dideoxypurine nucleosides may be useful prodrugs for the targeting of 2′,3′-dideoxyinosine (ddl) to the central nervous system. The purpose of this study was to evaluate the potential effectiveness of 6-chloro-2′,3′-dideoxypurine (6-CI-ddP) for the targeting of ddl to the brain. In vitro studies indicated that the adenosine deaminase-mediated biotransformation of 6-CI-ddP to ddl was more rapid in mouse brain homogenate than in mouse serum. The brain distribution of 6-CI-ddP and ddl was assessed in vivo in mice following intravenous and oral administration of the prodrug or parent drug. Brain concentrations of ddl were similar after intravenous administration of 6-CI-ddP or ddl. However, after oral administration of the 6-CI-ddP prodrug, significantly greater concentrations of ddl were seen in the brain compared to those found after oral administration of ddl. The brain:serum AUG ratio (expressed as a percentage) of ddl after intravenous administration of 50 mg kg−1 of the active nucleoside was 3%. Following oral administration of 250 mg kg−1 ddl, low concentrations of ddl were detected in the brain. Brain:serum AUC ratios following intravenous and oral administration of the prodrug 6-CI-ddP were 19–25%. Thus, brain:serum AUC ratios were 6- to 8-fold higher after prodrug administration than those obtained after administration of the parent nucleoside. Oral administration of 6-CI-ddP yielded concentrations of ddl in the brain similar to those obtained following intravenous administration. The results of this study provide further evidence that 6-CI-ddP may be a useful prodrug for delivering ddl to the central nervous system, particularly after oral administration.

Preparation and Characterization of Novel Brain Targeting Magnetic Nanoparticles Modified with Ascorbic Acid

NANO ◽  
2018 ◽  
Vol 13 (01) ◽  
pp. 1850008 ◽  
Author(s):  
Linhui Wang ◽  
Yi Zhao ◽  
Runxin Lu ◽  
Yao Peng ◽  
Li Guo ◽  
...  
Keyword(s):  
Ascorbic Acid ◽  
Magnetic Nanoparticles ◽  
Glucose Transporter ◽  
Drug Loading ◽  
Brain Homogenate ◽  
Brain Targeting ◽  
Glucose Transporter 1 ◽  
Cns Drug Delivery ◽  
The Brain

Magnetic targeting, which utilizes a magnetic field to specifically deliver therapeutic agents to the targeted regions, can greatly improve the treatment efficiency. Herein, ibuprofen-loaded brain targeting magnetic nanoparticles (AA-Ibu-PEG-DA@MNPs) modified with ascorbic acid (AA) for central nervous system (CNS) drug delivery was designed and synthesized in order to effectively deliver ibuprofen to the brain through Na[Formula: see text]-dependent vitamin C transporter 2 (SVCT2) and glucose transporter 1 (GLUT1). The brain targeting magnetic nanoparticles, AA-Ibu-PEG-DA@MNPs, have a particle size of 82.5[Formula: see text]nm, 2% drug loading capacity and limited cytotoxicity against bEnd.3 cells. What’s more, the nanoparticles maintained the magnetic property with a saturation magnetization level at 52.17[Formula: see text]emu/g and could release ibuprofen when incubated in different mediums, including various buffers, mice plasma and brain homogenate. The results indicate that the magnetic nanoparticles may have the potential to be a promising approach to selectively deliver drugs into the brain. This study may be conducive to the field of CNS drugs delivery.

scholarly journals Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation

2021 ◽  
Vol 12 ◽  
Author(s):  
Soraia Silva ◽  
Joana Bicker ◽  
Carla Fonseca ◽  
Nuno R. Ferreira ◽  
Carla Vitorino ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Common Mental Disorder ◽  
Drug Loading ◽  
Pharmacokinetic Studies ◽  
Brain Delivery ◽  
In Vivo Evaluation ◽  
The Brain

Depression is a common mental disorder. Its treatment with selective serotonin reuptake inhibitors (SSRIs) is effective only in a fraction of patients, and pharmacoresistance is increasing steadily. Intranasal (IN) drug delivery to the brain stands out as a promising strategy to improve current therapeutic approaches by operating as a shuttle to overcome the blood–brain barrier. This work aimed to simultaneously administer escitalopram and paroxetine by IN route to mice. For this purpose, three nanostructured lipid carriers (NLC1, NLC2, and BorNLC) and one nanoemulsion (NE) were tested for drug loading. After their characterization, investigation of their impact on nasal cell viability and SSRI permeability assays were performed, using a human nasal RPMI 2650 cell line in air–liquid interface. In vitro assays demonstrated that NLCs, including borneol (BorNLC), significantly increased escitalopram permeability (p < 0.01) and paroxetine recovery values (p < 0.05) in relation to the other formulations and non-encapsulated drugs. IN and intravenous (IV) pharmacokinetic studies performed in vivo with a single dose of 2.38 mg/kg demonstrated similar results for escitalopram brain-to-plasma ratios. IN administrations delayed escitalopram peak concentrations in the brain for 15–60 min and no direct nose-to-brain delivery was detected. However, encapsulation with BorNLC considerably decreased escitalopram exposure in the lungs (124 μg min/g) compared with free escitalopram by IN (168 μg min/g) and IV (321 μg min/g) routes. Surprisingly, BorNLC IN instillation increased concentration levels of paroxetine in the brain by five times and accelerated brain drug delivery. Once again, lung exposure was considerably lower with BorNLC (AUCt = 0.433 μg min/g) than that with IV administration (AUCt = 1.01 μg min/g) and non-encapsulated IN formulation (AUCt = 2.82 μg min/g). Direct nose-to-brain delivery was observed for paroxetine IN administration with a direct transport percentage (DTP) of 56.9%. If encapsulated, it increases to 74.2%. These results clearly emphasize that nose-to-brain delivery and lung exposure depend on the formulation and on the characteristics of the drug under investigation. NLCs seem to be an advantageous strategy for nose-to-brain delivery of lipophilic molecules, since they reduce systemic and lung exposure, thereby decreasing adverse effects. For hydrophilic compounds, NLCs are particularly important to decrease lung exposure after IN administration.

Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease

2021 ◽  
Vol 22 ◽  
Author(s):  
Ishnoor Kaur ◽  
Arun Kumar ◽  
Tapan Behl ◽  
Dhruv Setia
Keyword(s):  
Drug Delivery ◽  
Biomedical Applications ◽  
Drug Loading ◽  
Transport Mechanisms ◽  
Long Term Effects ◽  
Future Studies ◽  
Β Amyloid ◽  
The Brain

Abstract: One of the most common form of neurodegenerative disorders, Alzheimer’s disease poses a great threat to the patients all over the globe with about 5.7 million cases estimated by the Alzheimer’s Association Report of 2018. The disorder is a result of β-amyloid deposition in the brain, deteriorating the cognitive ability and learning processes, commonly in geriatric patients. The review significantly elaborates the superiority of nanotechnological formulations over conventional therapeutic strategies which exhibit numerous side effects, poor pharmacokinetic profiles and limited efficacy, as compared to the nano-medicinal approach. The review recognizes the need to establish an understanding of the transport mechanisms across the blood brain barrier, prior to the nanoparticle studies, followed by discussion on various nano-formulations, evi-dently supported by the outcome of various studies conducted to investigate the drug delivery portfolio of nanomedicines. Furthermore, the review portrays the challenges to overcome in future studies, like nanoparticle fabrication, drug loading capacity, blood residency time, toxicity regime, monitoring long term effects, in-vivo compatibility and production tech-niques, in order to enable the development of an optimized form of drug delivery process, which would achieve significant heights in the biomedical applications and bring about a revolution in the field of medicine and science.

Lipid-Coated Nanosized Drug Delivery Systems For An Effective Cancer Therapy

2020 ◽  
Vol 17 ◽  
Author(s):  
Ozge Esim ◽  
Canan Hascicek
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Cancer Treatment ◽  
Drug Delivery Systems ◽  
Polymeric Nanoparticles ◽  
Drug Loading ◽  
Delivery Systems ◽  
Inorganic Nanoparticles ◽  
Coated Nanoparticle

: Currently, despite many active compounds have been introduced to the treatment, cancer remains one of the most vital causes of mortality and reduced quality of life. Conventional cancer treatments may have undesirable consequences due to the continuously differentiating, dynamic and heterogeneous nature of cancer. Recent advances in the field of cancer treatment have promoted the development of several novel nanoformulations. Among them, the lipid coated nanosized drug delivery systems have gained an increasing attention by the researchers in this field owing to the attractive properties such as high stability and biocompatibility, prolonged circulation time, high drug loading capacity and superior in vivo efficacy. They possess the advantages of both the liposomes and polymeric nanoparticles which makes them a chosen one in the field of drug delivery and targeting. Core-shell type lipid-coated nanoparticle systems, which provide the most prominent advantages of both liposomes such as biocompatibility and polymeric/inorganic nanoparticles such as mechanic properties, offer a new approach to cancer treatment. This review discusses design and production procedures used to prepare lipid-coated nanoparticle drug delivery systems, their advantages and multifunctional role in cancer therapy and diagnosis, as well as the applications they have been used in.

scholarly journals Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

2019 ◽  
Vol 20 (8) ◽  
pp. 2014 ◽  
Author(s):  
Laura Rigon ◽  
Marika Salvalaio ◽  
Francesca Pederzoli ◽  
Elisa Legnini ◽  
Jason Thomas Duskey ◽  
...  
Keyword(s):  
Polymeric Nanoparticles ◽  
Plga Nanoparticles ◽  
Neurological Involvement ◽  
Lysosomal Storage ◽  
Enzyme Replacement ◽  
Organ Systems ◽  
General Improvement ◽  
The One ◽  
The Brain

Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the patients. The main treatment is represented by a weekly infusion of the functional enzyme, which cannot cross the blood-brain barrier and reach the central nervous system. In this study, a tailored nanomedicine approach based on brain-targeted polymeric nanoparticles (g7-NPs), loaded with the therapeutic enzyme, was exploited. Fibroblasts from MPSII patients were treated for 7 days with NPs loaded with the IDS enzyme; an induced IDS activity like the one detected in healthy cells was measured, together with a reduction of GAG content to non-pathological levels. An in vivo short-term study in MPSII mice was performed by weekly administration of g7-NPs-IDS. Biochemical, histological, and immunohistochemical evaluations of liver and brain were performed. The 6-weeks treatment produced a significant reduction of GAG deposits in liver and brain tissues, as well as a reduction of some neurological and inflammatory markers (i.e., LAMP2, CD68, GFAP), highlighting a general improvement of the brain pathology. The g7-NPs-IDS approach allowed a brain-targeted enzyme replacement therapy. Based on these positive results, the future aim will be to optimize NP formulation further to gain a higher efficacy of the proposed approach.

Sign in / Sign up

Export Citation Format

Share Document